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Summary Recombinant interleukin 2 (rIL-2), when given to patients with advanced malignant disease,
induces a limited beneficial effect, with only 20-30% of patients with solid tumours responding. This present
study has identified those patients with advanced colorectal cancer most likely to respond to rIL-2 therapy, by
analysis of serum cytokine levels, prior to and during rIL-2 treatment, documented in responders and
non-responders. Responders were found to have significantly lower pretreatment serum IL-6 and soluble IL-2
receptor levels (sIL-2R) than non-responders (P<0.01 and P<0.05 respectively). During rIL-2 infusion,
responders developed high circulating levels of IL-6 and had low constant levels of prostaglandin E2 (PGE2).
Non-responders failed to produce IL-6 and demonstrated elevated serum concentrations of PGE2, during
infusions of rIL-2. Thus, an enhanced ongoing IL-6 and sIL-2R response, prior to therapy, was detrimental to
subsequent treatment with rIL-2. Differential production and/or release of cytokines and prostaglandins,
during therapy, further determined the likelihood of response to rIL-2.
Interleukin 2 (IL-2) is a 15.5 kDa T cell-derived cytokine
which is integral to the proper activity of the immune system
(Erard et al., 1985). It stimulates the activation, proliferation
and differentiation of T and B cells, the generation and
enhanced cytolytic activity of natural killer (NK) and
lymphokine-activated killer (LAK) cells and the generation
and release of various cytokines (Henney et al., 1981; Grimm
et al., 1982). IL-2 induces, both in vitro and in vivo, T-cell
production of IL-2, IL-4 and gamma-interferon (y-IFN), and
monocyte release of IL-1, tumour necrosis factor (TNF-a)
and IL-6, as well as the release of the inhibitory eicosanoid
prostaglandin E2 (PGE2) (Schaafsma et al., 1991). Further-
more, IL-2 enhances the expression of the cell-surface recep-
tor for IL-2 (IL-2R) on T and B cells and monocytes (Lotze
et al., 1987). Binding of IL-2 to the a-subunit of the receptor
(R) results in the release of a 45 kDa cleaved soluble(s)
fragment (sIL-2R) (Rubin et al., 1986). sIL-2R is not known
to have agonist activity but is capable of binding with low
affinity to circulating IL-2 and may, in vivo, reduce the
bioavailability of exogenously administered IL-2 (Kondon et
al., 1988; Rubin et al., 1990).
Early animal experiments demonstrated that exogenously
administered IL-2 could induce the regression of a number of
experimental tumours (LaFreniere et al., 1985). Recombinant
IL-2 (rIL-2) has been given, alone or in combination with
other chemotherapeutic agents, to patients with advanced
cancers in an attempt to enhance host anti-tumour mechan-
isms and thus improve survival (Rosenberg et al., 1989). The
highest clinical response rates documented to date have been
achieved in patients with renal cancer and malignant
melanoma (Fisher et al., 1988; Parkinson et al., 1990). How-
ever, therapy for patients with other solid tumours, e.g.
colorectal cancer, has been disappointing, with maximal
clinical response rates of 20-30% being described (Hamblin
et al., 1990). The mechanism(s) underlying this tumour selec-
tivity has not been fully characterised but may be dependent,
in part, upon the ability of the host to generate an appropri-
ate cytokine response.
The monocyte-derived cytokines IL-1, IL-6 and TNF-a
and PGE2 exert regulatory influences upon the immune
system. Antigen interaction with monocytes results in the
early release of IL-1, TNF-oa and IL-6. These cytokines co-
stimulate each other's release from the monocyte/macrophage
population and also cooperate in a range of immune-
enhancing actions, e.g. induction of acute-phase protein
release (Zhong et al., 1993). Subsequent monocyte produc-
tion of PGE2 down-regulates the release of these cytokines
and directly inhibits the action of T-helper cells, responsible
for the production of IL-2 and IL-4. Sustained imbalances in
the release of IL-6 and PGE2 have been found in states of
anergy and sepsis (Redmond et al., 1991). The mechanisms
responsible for the different patterns of cytokine production
by monocytes are unknown. However, appropriate IL-6
release is necessary for the anti-cancer efficacy of rIL-2.
Several cytokines are known to influence the function of
the anti-cancer NK and LAK cells (von Rohr et al., 1993).
IL-2 and IL-6 are essential co-factors in the generation and
optimal cytolytic activity of these cells. PGE2, in vitro, can
inhibit LAK-cell function, and sIL-2R may limit the
availability of IL-2. NK and LAK cells are capable of lysing
allogeneic and, in the case of LAK cells, autologous tumour
cells, through both MHC- and non-MHC restricted pathways
(Mule et al., 1990). In patients with advanced colorectal
cancer, we have demonstrated that continuous administration
of rIL-2 results in maximum in vivo stimulation of NK
activity but suboptimal LAK cell cytotoxicity (Park et al.,
1992). The latter cells, however, could undergo maximum
stimulation with further in vitro incubation with rIL-2. IL-2
may therefore concurrently generate increased suppressor
mechanisms and/or activity through the release of certain
endogenous humoral mediators, e.g. PGE2 (Pelton et al.,
1991).
The aim of our study was therefore to define more pre-
cisely the pattern of cytokine (IL-4, IL-6, TNF-a, sIL-2R)
and prostaglandin (PGE2) release in patients with solid
cancers, prior to and during therapy. The patterns
documented offer possible explanations for the differential
effect on anti-cancer host defences and selective anti-tumour
efficacy of rIL-2 therapy.
Patients and methods
Patients
Twenty patients with metastatic or locally advanced colorec-
tal carcinoma (Dukes C or D) were studied. All patients had
an ambulatory performance status (Eastern Cooperative
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Oncology Group 0-1, Karnofsky >80%) with a life expec-
tancy greater than 3 months. Liver and renal function tests
were within normal limits and patelet and white cell counts
were above 120 x i091-' and 3 x i091'- respectively. No
patient had received systemic chemotherapy, radiotherapy or
immunotherapy for the 4 weeks prior to the rIL-2 infusion.
All patients gave written informed consent to participate in
the study, which was part of a prospective, randomised,
European study, and had been approved by the Joint Ethical
Committee of Grampian Health Board and Aberdeen
University. Patients were monitored in a surgical high-
dependency unit and hourly recordings of pulse, blood pres-
sure, temperature and urine output were documented.
Dosage ofrIL-2
A constant intravenous infusion of rIL-2 (Proleukin,
Eurocetus Corporation, Amsterdam, The Netherlands) was
administered for 5 days (120 h). Dosage was calculated ac-
cording to the schedule, 18 x 106 IU m-2 24 h-' for the total
of 120 h. No significant alteration in rate of infusion was
required because of severe toxicity. Forty-eight hours follow-
ing cessation of the rIL-2 infusion, patients received a bolus
intravenous injection of 5-fluorouracil (600 mg m-2) and
folinic acid (25 mgm-2), the chemotherapy being repeated
weekly for 3 weeks. At the end of this 4 week period,
constituting a cycle, patients were reassessed, and if there was
evidence of stasis or a clinical tumour response to the
disease, patients received further cycles up to a maximum of
6. However, if there was clear evidence of progression of
disease, no further immunotherapy was given.
Timing ofsample collection andpurification
Serum was collected from all patients at the start (prior to
infusion) and end of the rIL-2 administration (120 h) at all
cycles. Peripheral blood was collected without the use of a
tourniquet. In a further ten patients, serum was collected 0,
12, 24, 48, 72, 96 and 120 h from the start of the infusion
during the first cycle. Blood was allowed to clot and then
spun at 1,000 g for 10 min. Serum was removed and stored at
- 80°C until required for analysis. For the analysis of plasma
levels of PGE2, blood was collected in EDTA tubes in the
presence of the cyclo-oxygenase inhibitor indomethacin [1%
(w/v) final concentration] and stored at - 80°C, at pH 4.5,
titrated by the addition of acetic acid. IL-4, IL-6, sIL-2R and
TNF-x were assayed directly from the stored serum. Plasma
for PGE2 was purified by passage through Sep-Pak C18 col-
umns and eluting the sample with methanol.
Cytokine analysis
Interleukin 4, IL-6 and TNF-a were measured by an enzyme-
linked immunosorbent assay (ELISA) using the 'sandwich'
technique (Quantikine, British Biotechnology, Abington,
UK). Minimum detectable serum levels were 31.3 pgml-',
3.13 pg ml-' and 15.7 pg ml1' respectively. The coefficient of
variation (CV) of the assays was found to be less than 3%.
Soluble IL-2R (CD45) was measured using an ELISA plate
from Dako (Dakopatts, Glostrup, Denmark). The minimum
detectable serum level of sIL-2R was 16 U ml-' with a plate
CV of 4%. PGE2 was measured using an ELISA plate with a
minimum detectable level of 2 pgml-' (Biotrak, Amersham
Life Science, UK). Highest cross-reactivity was for PGE, at
7%. The CV of the plate was found to be 3%. In each assay,
a standard curve was constructed and all samples were
assayed in duplicate.
Response criteria
Clinically palpable disease (e.g. lymphadenopathy in neck)
was evaluated by careful caliper measurements. Impalpable
disease (e.g. pulmonary and hepatic metastases) was assessed
using a variety of modalities - ultrasonography, com-
puterised tomography and magnetic resonance imaging. Ap-
propriate plain radiography of selected anatomical areas was
also carried out. Using standard UICC criteria (Hayward et
al., 1977; Miller et al., 1981), a complete response (CR) was
defined as the absolute disappearance of all clinically detec-
table disease for at least 4 weeks. A partial response was
defined as a 50% or greater reduction in total tumour mass
as measured by the sum of the products of the two longest
perpendicular diameters of all measurable lesions. This status
had to remain unchanged for 4 weeks, with no simultaneous
progression of assessable disease or development of new
lesions. Stable disease (SD) was defined as a less than 25%
increase or a less than 50% decrease in total tumour size.
Progressive disease (PD) was defined as a 25% or greater
increase in tumour mass or the appearance of new
lesions.
Statistical analysis
Statistical analyses were done using non-parametric tests.
Grouped data were analysed with the Mann-Whitney U-test.
Serial recordings of grouped data are expressed as median
and interquartile range. Analysis of consecutive dependent
data was performed using ANOVA. All P-values are two-
tailed.
Results
Patient characteristics
Twenty patients were studied, ten females and ten males. The
age range was 36-71 years (median 63). No patient under-
went a complete response. Seven exhibited a partial response
(responders), seven had stasis of disease and six patients had
progressive disease (classified as non-responders). There was
no sex difference in those patients who responded (three
males, four females). Non-responders were classified as those
patients who had either stasis or progression of disease.
Pretreatment IL-6 and sIL-2R levels and response to rIL-2
Pretreatment serum IL-6 levels in the seven responders were
all less than 10 pg ml-l (range 3-8 pg ml-'; median
5 pg ml-') (Figure 1). In the 13 patients who did not respond
to therapy, the basal IL-6 level varied widely (range
6-151 pg ml'-l; median 24 pg ml-i). Those patients who re-
sponded to rIL-2 therapy had low (<10pgml-') pretreat-
ment serum IL-6 values compared with non-responders
(100% of responders vs 8% of non-responders) (U = 5,
P<0.001). Basal serum levels of sIL-2R (Figure 1), in those
patients who responded to treatment, were significantly lower
(range 250-675 IU ml-'; median 430 IU ml-l) than in the
non-responders (range 360-5,520 IU ml-'; median
1,190 IU ml-') (100% of responders vs 46% of non-
responders) (U= 14, P<0.05).
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Figure 1 Influence of pretreatment serum IL-6 and sIL-2R con-
centration upon likelihood of response. a, Responders (n = 7); b,
non-responders (n = 13).
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IL-6 levels during repeated cycles ofrIL-2
IL-6 was assayed at the beginning and end of each 120 h
infusion of rIL-2. In six of the seven patients who responded
to therapy, there was a consistent rise in serum IL-6 at the
end of each cycle (Figure 2). Values then returned to
pretreatment levels at the start of the next cycle. This pattern
was repeated with all subsequent cycles of rIL-2 infusion in
these patients. In one patient who responded clinically and
received five cycles of rIL-2 there was no change in serum
level of this cytokine during the infusions. In the 13 non-
responders, no such pattern was identified. Only one patient
exhibited an elevation in IL-6 -(during the first infusion).
Otherwise, serum IL-6 levels remained unchanged or fell
progressively.
sII-2R levels during repeated cycles ofrIL-2
All seven responders exhibited elevations in sIL-2R at the
end of each infusion. Peak values ranged from 4,240 to
6,160 IU ml-' (median 5,620 IU ml- -). Serum levels then fell,
but always remained above pretreatment values at the start
of the next cycle. One patient continued to have significantly
elevated serum levels of the receptor throughout all five
cycles. This pattern of potentiation was seen in 10 of the 13
non-responders (data not shown). Three exhibited no varia-
tion from baseline levels in serum concentrations at the end
of the infusion. Maximum levels attained in this group were
similar to those documented in the responders. In both
groups of patients, no decrease in peak values attained at
120 h was found.
IL-6 levels during thefirst rIL-2 infusion
Serum IL-6 was determined in ten patients (three responders,
seven non-responders) during the first 120 h infusion of rIL-2
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(Figure 3). As described above, basal levels in the non-
responders were significantly higher than in the responders.
These high values then fell progressively throughout the
infusion (120 h: 27 ± 5 pg ml-'). By contrast, in the re-
sponder group, low basal serum concentrations rose to a
peak at the end of the infusion (120 h: 97 ± 19 pgml-').
sIL-2R levels during thefirst rIL-2 infusion
Serum levels of sIL-2R rose progressively in both groups of
patients to peak at the end of the infusion (responders,
5,380± 450 IU ml-'; non-responders, 4,570 ± 520 IU ml-').
Other than basal values (see above) no significant differences
were identified in the magnitude or timing of the increase in
serum levels of the receptor in the two patient groups. A
stimulation index of the value at time t compared with basal
value for the two groups of patients was also carried out
(Figure 4). In the responding group of patients, levels were
significantly elevated compared with the non-responding
patients by 24 h and remained so until 120 h (P<0.01). A
peak stimulation index of 15 was achieved in the responding
group, whereas that for the non-responding group was only
1.87.
PGE2 during rIL-2 infusion
Basal serum concentrations of PGE2 were not significantly
different for the two groups (range 15-63pgml-'). In the
responder group, no significant alterations in serum levels
occurred during the infusions (Figure 5). The serum PGE2
concentration rose progressively throughout the infusions to
peak at 72 h (235 ± 25 pg ml-') and remained elevated until
120 h. Significant differences in serum level between the two
groups were attained by 48 h from commencement of the
infusions (P<0.05). These differences persisted for the
remainder of the rIL-2 infusions (48-120h).
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Figure 2 Serum concentrations of IL-6 in responders during
repeated infusions of rIL-2. Results expressed as median ± inter-
quartile range. DO, day 0; D5, day 5 of each 120 h rIL-2 infusion
of each cycle (C).
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Figure 4 Stimulation index for serum sIL-2R concentrations in
responders and non-responders during first infusion of rIL-2.
Median ± interquartile range. '*P<0.01, Mann-Whitney U-test
(time 0, 24 h). a, Responders; b, non-responders.
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Figure 3 Serum IL-6 concentrations for responders during first
infusion of rIL-2. Median ± interquartile range. P<0.05, Mann-
Whitney U-test (times 0, 24, 72, 96 and 120 h). a, Responders; b,
non-responders.
Figure 5 Serum concentrations of PGE2 for responders and
non-responders during first infusion of rIL-2. Median ± inter-
quartile range. P<0.05, Mann-Whitney U-test (times 48, 72, 96
and 120h). a, Responders; b, non-responders.
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IL-4 and TNF-c during rIL-2 infusion
IL-4 was not detected in any serum sample obtained from
either group of patients (responders/non-responders). Serum
levels of TNF-a were assayed in ten patients (three re-
sponders, seven non-responders). Pretreatment serum TNF-M
levels were all below detectable limits. In all but one patient
serum concentrations rose by 48 h of the infusion to detec-
table levels. Maximum values were achieved in these nine
patients by 92 h and the range was 80-220 pg ml-'. How-
ever, no differences in either peak value attained or the time
taken to achieve peak values were found between the two
groups of patients. The one patient who exhibited no serum
TNF-a response was a non-responder.
Discussion
Recombinant IL-2 has been administered to patients with
advanced cancer in an effort to enhance anti-cancer host
defence mechanisms and thus induce remissions (Mule et al.,
1985). Both enhanced in vivo NK- and LAK-cell cytolytic
activities and appropriate monocyte-derived cytokine release
have been postulated as important anti-cancer mechanisms
(Gemlo et al., 1988; von Rohr et al., 1993). While it is
recognised that NK- and LAK-cell activities correlate with
tumour responses in animal studies, this is less well estab-
lished in man (Mitchell et al., 1988). LAK-cell activity, in
vivo, has been found to be suboptimal in patients with
advanced colorectal cancer receiving continuous infusions of
rIL-2 (Park et al., 1992). Maximal activity of the LAK cells,
however, could be achieved by further in vitro incubation
with rIL-2. Pre-existing, or therapy-induced, circulating sup-
pressor factors appeared to be modifying host responses to
exogenous rIL-2. Imbalance in the production of the immune-
enhancing cytokines IL-1, IL-6 and TNF-x and the inhibi-
tory eicosanoid PGE2 may also modify the host anti-cancer
response to rIL-2.
While much is known of the cytokine regulatory influences
upon NK- and LAK-cell function, the relevance of the
therapy-induced generation of cytokines, in vivo, is poorly
understood. IL-6, TNF-.x, sIL-2R and y-IFN have all been
detected sporadically in the sera of patients receiving
immunotherapy (Gemlo et al., 1988; Urba et al., 1990).
However, the significance of these in vivo findings in relation
to anti-cancer effects is unclear at present. IL-6 promotes
NK- and LAK-cell generation and activity. It may also
directly mediate some of the anti-cancer effects of IL-2.
TNF-o enhances NK- and LAK-cell activity, as well as
inducing the disruption of tumour vascular architecture
through release of endonucleases and proteases (Nawroth &
Stern, 1986; Ostensen et al., 1987). Sustained elevations in
serum TNF-a have been correlated with response to rIL-2
therapy (Blay et al., 1990). The soluble IL-2 receptor is shed
from the membrane-bound p55 a-chain after ligand binding.
Circulating levels are therefore believed to be representative
of overall IL-2 activity, although cleavage of the solitary
a-chain does not result in signal transduction (Marcon et al.,
1988). IL-4 is a T cell-derived cytokine with pleiotropic
effects upon the immune system (Hill et al., 1992). It stimu-
lates the growth of activated T, B and NK cells. It also
enhances cytolytic T-cell activity, yet paradoxically reduces
LAK-cell killing (Smith et al., 1986; Treisman et al., 1990).
Activated monocytes have been shown to down-regulate the
activity of these cytokines, through the release of PGE2
(Chouaib et al., 1984; Wood et al., 1987). PGE2 inhibits
monocyte release of IL-1 and TNF-a, and the generation and
activity of NK and LAK cells (Grbic et al., 1991).
In this study, patients with advanced colorectal cancer
undergoing therapy with rIL-2 and chemotherapy were
evaluated. We have documented that patients with demon-
strable anti-tumour responses (responders) were more likely
to have low basal levels of both IL-6 and sIL-2R. Our results
suggest that in these patients there is an absence of an
ongoing immune, possibly anti-cancer, response and low
basal activity of cell-mediated immunity. In the non-
responders, on the other hand, there was a wide range of
basal levels of these cytokines. Very few (8%) had normal
serum IL-6 levels, while almost half (46%) had high levels of
sIL-2R, suggesting an ongoing immune response, albeit
ineffectual against advanced cancers. Although the subse-
quent augmented IL-6 response to rIL-2 therapy was highly
predictive (90%) of a beneficial anti-tumour response in the
first course of treatment, the sIL-2R levels bore no relation-
ship to the clinical responses documented. High basal levels
of IL-6 suggest the presence of a substantial population of
activated monocytes/macrophages responding to stimulatory
signals. Likewise, high basal levels of serum sIL-2R are the
result of increased serum concentrations of the cleaved
a-chain of the IL-2 receptor. Very high circulating levels of
IL-6 and sIL-2R are also found in patients with sepsis and
active autoimmune disease (e.g. rheumatoid arthritis),
confirming the postulate that IL-6 and sIL-2R are sensitive
barometers of perturbations of cell-mediated immunity.
A clear difference in the pattern of IL-6 production was
seen between these two groups of patients. In the responders,
IL-6 levels were always much higher at the end of the 5 day
infusion, with return to the pretreatment range at the start of
the subsequent infusion. This biorhythmic response was seen
in all the cycles of rIL-2 therapy. This implies a consistent
production of immune-enhancing cytokines in response to
exogenous rIL-2 and stimulation of the cells of the lympho-
reticular system. In contrast, no such pattern was seen in the
non-responders. Lack of generation of high levels of IL-6 in
response to rIL-2 is potentially detrimental and may limit
maximal NK/LAK-cell generation. This would be in keeping
with our previous data demonstrating suboptimal LAK-cell
activity in patients receiving rIL-2 therapy (Park et al., 1992).
No difference was seen in the serum levels of sIL-2R during
the infusions in the two groups of patients. Circulating sIL-
2R levels increased in all responders and in the majority of
non-responders at the end of each 5 day infusion. Increased
binding of rIL-2 to the a-chain of the IL-2 receptor may be
occurring here. However, it is uncertain whether this is part
of the low-affinity isolated p55 receptor which does not trans-
duce signals or a fragment of the high-affinity x/p-hetero-
dimer. These very high levels of sIL-2R in the serum may
also reflect decreased urinary excretion secondary to rIL-2-
induced renal tubular dysfunction (Lotze et al., 1986). Our
data identify no differential pattern in absolute levels, during
therapy, of serum concentrations of sIL-2R between re-
sponders and non-responders. This contradicts the view that
sIL-2R may bind to exogenously administered rIL-2 and thus
reduce its efficacy. If that were the case, clinical response
would be associated with lower circulating levels of this
receptor. However, such binding of IL-2 to the Tac fragment,
to our knowledge, has only been demonstrated in vitro and as
such may not be representative of in vivo physiology (Rubin
et al., 1986). Such binding of the sIL-2R fragment to rIL-2
that does occur in the circulation appears not to influence the
efficacy of rIL-2.
Analysis of the serum cytokine concentrations during the
first infusion revealed two distinct patterns of cytokine pro-
duction. In those patients who responded to therapy, there
was progressive elevation in the serum IL-6 with no change
in serum PGE2 concentration. In non-responders, on the
other hand, serum IL-6 concentrations fell with correspond-
ingly increasing levels of PGE2 during the rIL-2 infusion. A
finely balanced interaction between the stimulatory IL-6 and
the inhibitory PGE2 thus may determine the effect on anti-
cancer defences and the response to therapy. No intra-
infusion difference in levels of sIL-2R was seen. Lack of
detectable IL-4 at any time point is open to various inter-
pretations; in situ generation and rapid utilisation may partly
explain the undetectable levels. We have also analysed the
serum levels of TNF-a in our patients during the rIL-2
infusion. Serum levels rose in nine of the ten patients studied.
Peak levels were attained at 72 h from the commencement of
infusion and were of the order of 100-150pgml-'. How-
ever, no differential TNF-x release was seen between re-1134 D.J. DEEHAN et al.
sponders and non-responders. While persistent production of
this cytokine has been reported to predict response to
therapy, this appears to be of little value when monitored
prior to initiation of therapy (Blay et al., 1990). We have
demonstrated, however, a relationship between TNF-m levels
and fluid retention, possibly through a 'vascular leak'
mechanism (Deehan et al., 1994).
To the best of our knowledge, this is the first study to
document that serum concentrations of IL-6 and sIL-2R can
predict the likelihood of response of patients with cancer to
therapy with rIL-2. These findings both complement and
extend our previous reports on the value of acute-phase
reactants in patients undergoing therapy with rIL-2 (Broom
et al., 1992). Low (i.e. <10 pg mll), pretreatment serum
IL-6 levels afford a highly specific indication of likelihood of
response to rIL-2-based immunotherapy in patients with
advanced colorectal cancer. Further confirmation could be
obtained from monitoring the serum levels of IL-6 during
subsequent therapy, and identifying an appropriate
immunological response. However, the additional determina-
tion of circulating C-reactive protein levels would only con-
cur with such a prediction but would not strengthen the
power of such a test. In summary, patients with low cir-
culating levels, particularly IL-6, are more likely to respond.
Furthermore, two distinct patterns of host cytokine (i.e. IL-6,
sIL-2R and PGE2) response are identified. Patients in whom
the tumour has not induced a significant host response
generate high serum IL-6 and low PGE2 levels; these patients
clinically respond to rIL-2 therapy. On the other hand, in
those patients in whom the tumour appears to have activated
host responses, rIL-2 induces an inhibition of IL-6 release
with concurrent release ofhigh levels ofPGE2. This differential
modulation of monocyte/macrophage activity may contribute
to the suppressor mechanisms responsible for the suboptimal
generation of LAK-cell activity and poor clinical responses
documented in vivo with rIL-2 infusion in some patients.
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